83 filings
ARS
2023 FY
TRDA
Entrada Therapeutics Inc
29 Apr 24
Annual report to shareholders
9:14am
DEFA14A
TRDA
Entrada Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
9:13am
DEF 14A
TRDA
Entrada Therapeutics Inc
Definitive proxy
29 Apr 24
9:11am
PRE 14A
TRDA
Entrada Therapeutics Inc
19 Apr 24
Preliminary proxy
7:00am
S-8
TRDA
Entrada Therapeutics Inc
13 Mar 24
Registration of securities for employees
7:36am
8-K
u565k3
13 Mar 24
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
7:08am
8-K
cc4xc16m57zyx6 1m86s
3 Jan 24
Departure of Directors or Certain Officers
7:16am
UPLOAD
9fggtwo6j3zrf
20 Dec 23
Letter from SEC
12:00am
8-K
khrsmcix8 xk0xwr
6 Dec 23
Departure of Directors or Certain Officers
7:00am
CORRESP
8tzutft2wqcq
6 Dec 23
Correspondence with SEC
12:00am
8-K
l4238hrf5i
22 Nov 23
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
7:35am
UPLOAD
6f1n3k18ejsdxc
21 Nov 23
Letter from SEC
12:00am
CORRESP
fwi7w8tm9g8h
13 Nov 23
Correspondence with SEC
12:00am
8-K
bngc4uou
7 Nov 23
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
7:08am
8-K
4859w7r5 y19
1 Nov 23
Entry into a Material Definitive Agreement
7:01am
UPLOAD
ruy2i
1 Nov 23
Letter from SEC
12:00am
8-K
3fcoabpn3
29 Sep 23
Entry into a Material Definitive Agreement
4:39pm
424B5
6osa1ga
29 Sep 23
Prospectus supplement for primary offering
4:35pm